Your browser doesn't support javascript.
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
Arq. bras. cardiol ; 95(3): 283-288, set. 2010. ilus, tab
Artigo em Português | LILACS | ID: lil-560553

RESUMO

FUNDAMENTO: O uso da rosiglitazona tem sido o objeto de extensas discussões. OBJETIVO: Avaliar os efeitos da rosiglitazona nas artérias ilíacas, no local da injúria e na artéria contralateral, de coelhos hipercolesterolêmicos submetidos à lesão por cateter-balão. MÉTODOS: Coelhos brancos machos receberam uma dieta hipercolesterolêmica através de gavagem oral por 6 semanas e foram divididos em 2 grupos: grupo rosiglitazona (GR - 14 coelhos tratados com rosiglitazona por 6 semanas) e grupo controle (GC - 18 coelhos sem rosiglitazona). Os animais foram submetidos a lesão por cateter-balão na artéria ilíaca direita no 14º dia. RESULTADOS: Na artéria ilíaca contralateral, não houve diferença significante na razão entre as áreas intimal e medial (RIM) entre os grupos GR e GC. A rosiglitazona não reduziu a probabilidade de lesões tipo I, II ou III (72,73 por cento vs 92,31 por cento; p=0,30) e lesões tipo IV ou V (27,27 por cento vs 7,69 por cento; p=0,30). Na artéria ilíaca homolateral, a área intimal era significantemente menor no GR quando comparado ao GC (p = 0,024). A área luminal era maior no GR quando comparado ao GC (p < 0,0001). Houve uma redução significante de 65 por cento na IMR no GR quando comparado ao GC (p = 0,021). Nenhum dos critérios histológicos para lesões ateroscleróticas tipos I a V (American Heart Association) foram encontrados na artéria ilíaca homolateral. CONCLUSÃO: Esses achados demonstram que a administração de rosiglitazona por 6 semanas impede a aterogênese no local da lesão, mas não em um vaso distante do sítio da lesão.


BACKGROUND: Rosiglitazone has been the focus of extensive discussion. OBJECTIVE: To evaluate the effects of rosiglitazone on iliac arteries, both at the injury site and the contralateral artery, of hypercholesterolemic rabbits undergoing balloon catheter injury. METHODS: White male rabbits were fed a hypercholesterolemic diet by oral gavage for 6 weeks and divided into two groups as follows: rosiglitazone group (14 rabbits treated with rosiglitazone during 6 weeks) and the control group (18 rabbits without rosiglitazone). Animals underwent balloon catheter injury of the right iliac artery on the 14th day. RESULTS: In the contralateral iliac artery, there was no significant difference in the intima/media layer area ratio (IMR) between the control and rosiglitazone groups. Rosiglitazone did not reduce the probability of type I, II, or III lesions (72.73 percent vs 92.31 percent; p=0.30) and type IV or V lesions (27.27 percent vs 7.69 percent; p=0.30). As for the homolateral iliac artery, the intimal area was significantly lower in the rosiglitazone group, as compared to the control group (p = 0.024). The luminal layer area was higher in the rosiglitazone group vs. the control group (p < 0.0001). There was a significant reduction of 65 percent in the IMR in the rosiglitazone group vs the control group (p = 0.021). None of the histological criteria for type I-V atherosclerotic lesions (American Heart Association) were found in the homolateral iliac artery. CONCLUSION: These findings demonstrate that rosiglitazone given for 6 weeks prevents atherogenesis at the injury site, but not in a vessel distant from the injury site.


FUNDAMENTO: El uso de rosiglitazona ha estado siendo el objeto de extensas discusiones. OBJETIVO: Evaluar los efectos de la rosiglitazona en las arterias ilíacas, en el local de la injuria y en la arteria contralateral, de conejos hipercolesterolémicos sometidos a la lesión por catéter-balón. MÉTODOS: Conejos blancos machos recibieron una dieta hipercolesterolémica a través de gavage oral por 6 semanas y se los dividieron en 2 grupos: grupo rosiglitazona (GR - 14 conejos tratados con rosiglitazona por 6 semanas) y grupo control (GC - 18 conejos sin rosiglitazona). Los animales se sometieron a lesión por catéter-balón en la arteria ilíaca derecha en el 14º día. RESULTADOS: En la arteria ilíaca contralateral, no hubo diferencia significativa en la razón entre las áreas íntima y media (RIM) entre los grupos GR y GC. La rosiglitazona no redujo la probabilidad de lesiones tipo I, II ó III (72,73 por ciento vs 92,31 por ciento; p=0,30) y lesiones tipo IV ó V (27,27 por ciento vs 7,69 por ciento; p=0,30). En la arteria ilíaca homolateral, el área intima era significantemente menor en el GR cuando comparado al GC (p = 0,024). El área luminal era mayor en el GR cuando comparado al GC (p < 0,0001). Hubo una reducción significante del 65 por ciento en la IMR en el GR cuando comparado al GC (p = 0,021). Ningún de los criterios histológicos para lesiones ateroscleróticas tipos I a V (American Heart Association) se encontraron en la arteria ilíaca homolateral. CONCLUSIÓN: Estos hallazgos demuestran que la administración de rosiglitazona por 6 semanas impide la aterogénesis en el local de la lesión, pero no en un vaso distante del sitio de la lesión.


Assuntos
Animais , Masculino , Coelhos , Aterosclerose/prevenção & controle , Hipercolesterolemia/complicações , Artéria Ilíaca/efeitos dos fármacos , Neointima/etiologia , Tiazolidinedionas/farmacologia , Anti-Inflamatórios/farmacologia , Modelos Animais de Doenças , Hipercolesterolemia/metabolismo , Artéria Ilíaca/lesões , Artéria Ilíaca/metabolismo , Artéria Ilíaca/patologia , Neointima/metabolismo , Distribuição Aleatória
2.
Arq Bras Cardiol ; 95(3): 283-8, 2010 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-20676587

RESUMO

BACKGROUND: Rosiglitazone has been the focus of extensive discussion. OBJECTIVE: To evaluate the effects of rosiglitazone on iliac arteries, both at the injury site and the contralateral artery, of hypercholesterolemic rabbits undergoing balloon catheter injury. METHODS: White male rabbits were fed a hypercholesterolemic diet by oral gavage for 6 weeks and divided into two groups as follows: rosiglitazone group (14 rabbits treated with rosiglitazone during 6 weeks) and the control group (18 rabbits without rosiglitazone). Animals underwent balloon catheter injury of the right iliac artery on the 14th day. RESULTS: In the contralateral iliac artery, there was no significant difference in the intima/media layer area ratio (IMR) between the control and rosiglitazone groups. Rosiglitazone did not reduce the probability of type I, II, or III lesions (72.73% vs 92.31%; p=0.30) and type IV or V lesions (27.27% vs 7.69%; p=0.30). As for the homolateral iliac artery, the intimal area was significantly lower in the rosiglitazone group, as compared to the control group (p = 0.024). The luminal layer area was higher in the rosiglitazone group vs. the control group (p < 0.0001). There was a significant reduction of 65% in the IMR in the rosiglitazone group vs the control group (p = 0.021). None of the histological criteria for type I-V atherosclerotic lesions (American Heart Association) were found in the homolateral iliac artery. CONCLUSION: These findings demonstrate that rosiglitazone given for 6 weeks prevents atherogenesis at the injury site, but not in a vessel distant from the injury site.


Assuntos
Aterosclerose/prevenção & controle , Hipercolesterolemia/complicações , Artéria Ilíaca/efeitos dos fármacos , Neointima/etiologia , Tiazolidinedionas/farmacologia , Animais , Anti-Inflamatórios/farmacologia , Modelos Animais de Doenças , Hipercolesterolemia/metabolismo , Artéria Ilíaca/lesões , Artéria Ilíaca/metabolismo , Artéria Ilíaca/patologia , Masculino , Neointima/metabolismo , Coelhos , Distribuição Aleatória , Rosiglitazona
3.
Thromb J ; 6: 12, 2008 Aug 27.
Artigo em Inglês | MEDLINE | ID: mdl-18752684

RESUMO

OBJECTIVES: To analyse the effects of rosiglitazone administered at different times on neointimal formation in hypercholesterolemic rabbits following vascular injury. METHODS: Thirty-nine rabbits on a hypercholesterolemic diet were included. The animals underwent balloon catheter injury to the right iliac artery on day 14. They were divided into three groups as follows: control group, 13 rabbits without rosiglitazone; group I, 13 rabbits treated with rosiglitazone (3 mg/Kg body weight/day) for 28 days after the vascular injury; and group II, 13 rabbits treated with rosiglitazone (3 mg/Kg body weight/day) during all the experiment (42 days). Histological analysis was done by an experienced pathologist who was unaware of the rosiglitazone treatment. Histomorphometric parameters were performed by calculation of the luminal and intimal layer area, and intima/media layer area ratio (the area of the intimal layer divided by the area of the medial layer). RESULTS: Intimal area was significantly lower in group II vs. CG (p = 0.024) and group I (p = 0.006). Luminal layer area was higher in group II vs. CG (p < 0.0001) and group I (p < 0.0001). Intima/media layer area ratio was equal between CG and group I. Intima/media layer ratio area was significantly lower in group II vs. control group (p < 0.021) and group I (p < 0.003). There was a significant reduction of 65% and 71% in intima/media layer area ratio in group II vs. control group and group I, respectively. CONCLUSION: Pretreatment with rosiglitazone in hypercholesterolemic rabbits submitted to vascular injury significantly reduces neointimal formation.

4.
Thromb J ; 6: 4, 2008 May 16.
Artigo em Inglês | MEDLINE | ID: mdl-18485218

RESUMO

BACKGROUND: The objective was to evaluate the effects of rosiglitazone on iliac arteries of hypercholesterolemic rabbits undergoing balloon catheter injury in the contralateral iliac arteries. METHODS: White male rabbits were fed a hypercholesterolemic diet for 6 weeks and divided into two groups as follows: rosiglitazone group, 14 rabbits treated with rosiglitazone (3 mg/Kg body weight/day) during 6 weeks; and control group, 18 rabbits without rosiglitazone treatment. All animals underwent balloon catheter injury of the right iliac artery on the fourteenth day of the experiment. RESULTS: There was no significant difference in intima/media layer area ratio between the control group and the rosiglitazone group. Rosiglitazone did not reduce the probability of lesions types I, II, or III (72.73% vs. 92.31%; p = 0.30) and types IV or V (27.27% vs. 7.69%; p = 0.30). There were no differences in the extent of collagen type I and III deposition or in the percentage of animals with macrophages in the intima layer. The percentage of rabbits with smooth muscle cells in the intima layer was higher in rosiglitazone group (p = 0.011). CONCLUSION: These findings demonstrate that rosiglitazone given for 6 weeks did not prevent atherogenesis at a vessel distant from the injury site.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA